We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Teva-Ivax Merger Puts Spotlight On Authorized Generics

Law360 (July 28, 2005, 12:00 AM EDT) -- Teva Pharmaceutical Industries Ltd.’s $7.4 billion purchase of Ivax Corp. will once again propel the Israeli drug maker past Novartis as a leader in the $58-billion worldwide market for generic drugs....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.